Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease
about
The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease.Complex neuroprotective and neurotoxic effects of histone deacetylases.HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
P2860
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease
description
2016 nî lūn-bûn
@nan
2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@ast
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@en
Development of Improved HDAC6 ...... l Charcot-Marie-Tooth Disease.
@nl
type
label
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@ast
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@en
Development of Improved HDAC6 ...... l Charcot-Marie-Tooth Disease.
@nl
prefLabel
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@ast
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@en
Development of Improved HDAC6 ...... l Charcot-Marie-Tooth Disease.
@nl
P2860
P50
P1433
P1476
Development of Improved HDAC6 ...... al Charcot-Marie-Tooth Disease
@en
P2093
Matthew Jarpe
Veronick Benoy
P2860
P2888
P304
P356
10.1007/S13311-016-0501-Z
P577
2016-12-12T00:00:00Z